Olema Pharmaceuticals, Inc. (OLMA)
7.25
+0.14
(+1.97%)
USD |
NASDAQ |
Oct 20, 16:00
7.14
-0.11
(-1.52%)
After-Hours: 20:00
Olema Pharmaceuticals Research and Development Expense (TTM) : 190.19M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 190.19M |
| March 31, 2026 | 176.30M |
| December 31, 2025 | 157.70M |
| September 30, 2025 | 146.78M |
| June 30, 2025 | 140.05M |
| March 31, 2025 | 125.26M |
| December 31, 2024 | 124.52M |
| September 30, 2024 | 118.09M |
| June 30, 2024 | 104.32M |
| March 31, 2024 | 93.20M |
| December 31, 2023 | 86.14M |
| September 30, 2023 | 81.85M |
| Date | Value |
|---|---|
| June 30, 2023 | 80.03M |
| March 31, 2023 | 89.09M |
| December 31, 2022 | 82.27M |
| September 30, 2022 | 76.66M |
| June 30, 2022 | 71.56M |
| March 31, 2022 | 56.42M |
| December 31, 2021 | 51.10M |
| September 30, 2021 | 41.41M |
| June 30, 2021 | 33.56M |
| March 31, 2021 | 23.60M |
| December 31, 2020 | 13.70M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| SELLAS Life Sciences Group, Inc. | 20.35M |
| Puma Biotechnology, Inc. | 71.44M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |